Display options
Cite
Yari H, Gali H, Awasthi V. Nanoparticles for Targeting of Prostate Cancer. Curr Pharm Des. 2020;26(42):5393-5413doi: 10.2174/1381612826666200721001500.
Yari, H., Gali, H., & Awasthi, V. (2020). Nanoparticles for Targeting of Prostate Cancer. Current pharmaceutical design, 26(42), 5393-5413. https://doi.org/10.2174/1381612826666200721001500
Yari, Hooman, et al. "Nanoparticles for Targeting of Prostate Cancer." Current pharmaceutical design vol. 26,42 (2020): 5393-5413. doi: https://doi.org/10.2174/1381612826666200721001500
Yari H, Gali H, Awasthi V. Nanoparticles for Targeting of Prostate Cancer. Curr Pharm Des. 2020;26(42):5393-5413. doi: 10.2174/1381612826666200721001500. PMID: 32693761.
Copy Download .nbib Format: NLM
Share it on

Curr Pharm Des. 2020;26(42):5393-5413. doi: 10.2174/1381612826666200721001500.

Nanoparticles for Targeting of Prostate Cancer.

Current pharmaceutical design

Hooman Yari, Hariprasad Gali, Vibhudutta Awasthi

Affiliations

  1. Department of Pharmaceutical Sciences, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.

PMID: 32693761 DOI: 10.2174/1381612826666200721001500

Abstract

Prostate cancer (PCa) is the leading cause of death by cancer in men. Because of the drastic decline in the survival rate of PCa patients with advanced/metastatic disease, early diagnosis of disease and therapy without toxic side effects is crucial. Chemotherapy is widely used to control the progression of PCa at the later stages; however, it is associated with off-target toxicities and severe adverse effects due to the lack of specificity. Delivery of therapeutic or diagnostic agents by using targeted nanoparticles is a promising strategy to enhance accuracy and sensitivity of diagnosis of PCa and to increase efficacy and specificity of therapeutic agents. Numerous efforts have been made in past decades to create nanoparticles with different architectural bases for specific delivery payloads to prostate tumors. Major PCa associated cell membrane protein markers identified as targets for such purposes include folate receptor, sigma receptors, transferrin receptor, gastrin-releasing peptide receptor, urokinase plasminogen activator receptor, and prostate specific membrane antigen. Among these markers, prostate specific membrane antigen has emerged as an extremely specific and sensitive targetable marker for designing targeted nanoparticle-based delivery systems for PCa. In this article, we review contemporary advances in design, specificity, and efficacy of nanoparticles functionalized against PCa. Whenever feasible, both diagnostic as well as therapeutic applications are discussed.

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Keywords: Nanoparticle; and prostate specific membrane antigen; folate receptor; gastrin-releasing peptide receptor; prostate cancer; sigma receptors; transferrin receptor; urokinase plasminogen activator receptor

MeSH terms

Publication Types